Ocular Therapeutix (OCUL) Reiterated at Market Outperform by Citizens Amid Litigation

March 24, 2026 4:23 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $34.00 price target on Ocular Therapeutix (NASDAQ: OCUL).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found